Sandoz Optimistic On Biosimilars As It Reprioritizes US Portfolio

 
• By Jessica Merrill

Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.

Carol Lynch, Sandoz US
Sandoz US President Carol Lynch • Source: Sandoz

More from Strategy

More from Business